Phase 1 Study to Evaluate the Safety and Tolerability of VK2735

NCT05203237 · Completed

Last updated 2026-05-28

This clinical trial is testing the safety and tolerability of the drug VK2735 in adults with weight loss or nonalcoholic steatohepatitis (NASH).

Status Completed The study has finished.

Phase Phase 1 Checks safety and dosing in a small group.

Type Interventional (clinical trial)

Design Randomized, double-blind treatment study

Participants 92 people

Who can join Ages 18–65 · all sexes Healthy volunteers accepted.

Timeline Started 2021-12 · est. completion 2024-12

Where 1 site · Australia

What this study is testing ClinicalTrials.gov NCT05203237 ↗

Description as written by the study sponsor.

This is a Phase 1, randomized, double-blind, placebo-controlled single and multiple ascending dose study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of VK2735 in healthy adults and otherwise healthy adults who have an increased body mass index (BMI).

Treatments tested

VK2735 Biologic

Administered SC
Placebo Biologic

Administered SC
VK2735 Placebo Drug

Administered orally
VK2735 Drug Drug

Administered orally

Main thing measured	Incidence of treatment-emergent adverse events (TEAEs) and treatment-emergent serious AEs (TESAEs)
Sponsor	Viking Therapeutics, Inc.
Conditions studied	Weight Loss, NASH
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT05203237 ↗